Company Overview: Abeona

Industry News

17 Oct

Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the pricing of an underwritten public offering of five million shares of common stock at a public offering...

Read more

16 Oct

Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies

Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs Company receives infusion of an additional $5 million from exercise of outstanding warrants, totaling $18.85 million in proceeds NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc.  (ABEO), a...

Read more

28 Sep

Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

–Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation –Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics Development and Quality Management CLEVELAND, Sept. 28, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing...

Read more

17 Aug

Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host its inaugural Research and Development (R&D) Day event for the institutional investment community in New York...

Read more

16 Aug

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia....

Read more

25 Jul

Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer

NEW YORK and CLEVELAND, July 25, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that Juan Ruiz, M.D., Ph.D., MBA has joined the company as Chief Medical Officer. He will be responsible...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address